Skip to main content
. 2020 Oct 5;10:542007. doi: 10.3389/fonc.2020.542007

Figure 5.

Figure 5

14-3-3ζ silencing enhances the sensitivity of EGFR-mutant LUAD to EGFR-TKIs in a mouse xenograft model. (A) Representative images of tumors at 28 days after inoculation using H1975/Ctrl or H1975/14-3-3ζ-shRNA cells treated with PBS or gefitinib. The Ctrl group consisted of mice inoculated with H1975/scrambled-shRNA cells. In the 14-3-3ζ-shRNA group, mice were inoculated with 14-3-3ζ-silenced H1975 cells. In the Ctrl + gefitinib group, mice were inoculated with control H1975 cells and treated with gefitinib. In the 14-3-3ζ-shRNA + gefitinib group, mice were inoculated with 14-3-3ζ-silenced H1975 cells and treated with gefitinib. (B) Tumor growth curves in nude mice injected with H1975/Ctrl or H1975/14-3-3ζ-shRNA cells treated with PBS or gefitinib. N = 4 for each group. (C) Tumor volumes at day 28 after inoculation. Left (black column), average tumor volumes at day 28 after inoculation with H1975/Ctrl or H1975/14-3-3ζ- shRNA cells in mice treated with PBS; right (white column), average tumor volumes at day 28 after inoculation of H1975/Ctrl or H1975/14-3-3ζ- shRNA cells in mice treated with gefitinib. *p < 0.05.